omilancor
Ulcerative Colitis
Key Facts
About NImmune Biopharma
NImmune Biopharma is a private, late-clinical-stage biotech based in San Diego, pioneering a novel approach to treating autoimmune diseases via the LANCL2 pathway. Its lead asset, omilancor, is positioned as a potential first- and best-in-class oral therapeutic for inflammatory bowel disease (IBD), with a Phase 3 readout expected in 2026. The company is led by a seasoned team with deep immunology and biotech development experience and utilizes a proprietary AI platform (TITAN-X) to identify targets and expand its pipeline. NImmune is pre-revenue and focused on advancing its clinical programs to address significant unmet needs in autoimmune conditions.
View full company profileAbout NImmune Biopharma
NImmune Biopharma is a private, late-clinical-stage biotech based in San Diego, pioneering a novel approach to treating autoimmune diseases via the LANCL2 pathway. Its lead asset, omilancor, is positioned as a potential first- and best-in-class oral therapeutic for inflammatory bowel disease (IBD), with a Phase 3 readout expected in 2026. The company is led by a seasoned team with deep immunology and biotech development experience and utilizes a proprietary AI platform (TITAN-X) to identify targets and expand its pipeline. NImmune is pre-revenue and focused on advancing its clinical programs to address significant unmet needs in autoimmune conditions.
View full company profileOther Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BEN-8744 | BenevolentAI | Phase 1b |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |